FDA Requests Public Comment on Proposed Collection of Information for Reporting of Biological Product Deviations in Manufacturing

Summary

The Food and Drug Administration (FDA) is requesting public comment on a proposed collection of information related to the reporting of biological product deviations in manufacturing, which has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.